Breaking Finance News

A statement released earlier today by Zacks Investment Research about Baxter International Inc (NYSE:BAX) bumps the target price to $53.00

Displaying a price of $46.98, Baxter International Inc (NYSE:BAX) traded 1.47% higher on the day. The last stock price is up 4.75% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Baxter International Inc has recorded a 50-day average of $47.02 and a two hundred day average of $45.51. Trade Volume was down over the average, with 478,971 shares of BAX changing hands under the typical 3,713,650

In a report issued 10/13/2016 Zacks Investment Research raised the target price of Baxter International Inc (NYSE:BAX) to $53.00 stating a potential upside of 0.13%.

Performance Chart

Baxter International Inc (NYSE:BAX)

With a total market value of $0, Baxter International Inc has 52 week low of $32.96 and a one year high of $49.49 with a price-earnings ratio of 5.47 .

Also covering Baxter International Inc's price target, a total of 11 brokers have issued a report on the stock. The average stock price target is $48.82 with 0 firms rating the stock a strong buy, 3 analysts rating the company a buy, eleven equity analysts rating the company a hold, 1 brokerage rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Baxter International Inc (NYSE:BAX)

Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.